France Keytruda Market Size & Outlook, 2026-2033
Global Market
Related Markets
France keytruda market highlights
- The France keytruda market generated a revenue of USD 1,430.2 million in 2025 and is expected to reach USD 1,132.3 million by 2033.
- The France market is expected to grow at a CAGR of -3.8% from 2026 to 2033.
- In terms of segment, lung cancer was the largest revenue generating application in 2025.
- Breast Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Keytruda market data book summary
| Market revenue in 2025 | USD 1,430.2 million |
| Market revenue in 2033 | USD 1,132.3 million |
| Growth rate | -3.8% (CAGR from 2026 to 2033) |
| Largest segment | Lung cancer |
| Fastest growing segment | Breast Cancer |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma, Head and Neck Cancer, Gastric Cancer, Urothelial Cancer |
| Key market players worldwide | Merck & Co Inc, Bristol-Myers Squibb Co, Roche Holding AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Amgen Inc, Samsung Bioepis, Bio-Thera Solutions |
Other key industry trends
- In terms of revenue, France accounted for 4.6% of the global keytruda market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany keytruda market is projected to lead the regional market in terms of revenue in 2033.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 844.5 million by 2033.
France’s Keytruda market is growing due to increasing adoption in lung, gastric, and bladder cancers, along with government initiatives promoting immunotherapy.
Regulatory approvals and expanded public healthcare coverage support market growth. However, cost containment policies, stringent drug pricing negotiations, and competition from emerging biologics could hinder long-term expansion.
No credit card required*
Publish Date: Dec 23, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Keytruda Market Scope
Keytruda Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| Samsung Bioepis | View profile | 501-1000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbioepis.com |
| Bio-Thera Solutions | View profile | 251-500 | Guangzhou, Guangdong, China, Asia | bio-thera.com/EN/ |
France Keytruda Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Keytruda Market Outlook will help companies and investors design strategic landscapes.
Lung Cancer was the largest segment with a revenue share of 27.49% in 2025.
Horizon Databook has segmented the France keytruda market based on lung cancer, breast cancer, melanoma, hodgkin lymphoma, head and neck cancer, gastric cancer, urothelial cancer covering the revenue growth of each sub-segment from 2021 to 2033.
France’s Keytruda market is growing due to increasing adoption in lung, gastric, and bladder cancers, along with government initiatives promoting immunotherapy.
Regulatory approvals and expanded public healthcare coverage support market growth. However, cost containment policies, stringent drug pricing negotiations, and competition from emerging biologics could hinder long-term expansion.
- France Keytruda Market Application Outlook (Revenue, USD Million , 2021-2033)
- Lung Cancer
- Breast Cancer
- Melanoma
- Hodgkin Lymphoma
- Head and Neck Cancer
- Gastric Cancer
- Urothelial Cancer
- Others
- France Keytruda Market Payer Outlook (Revenue, USD Million , 2021-2033)
- Commerical/Private
- Public
- France Keytruda Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Specialty Pharmacy
Reasons to subscribe to Keytruda Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Keytruda Market Outlook databook
- Our clientele includes a mix of Keytruda Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Keytruda Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Keytruda Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Keytruda Market, 2021-2033 (US$M)
France keytruda market statistics, by application, 2021-2033 (US$M)
